These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 4038373)
21. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006 [TBL] [Abstract][Full Text] [Related]
22. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
24. [Thrombolytic therapy as pretreatment before vascular operations and radiologic interventions]. Laczkó A; Szabó GV; Szeberin Z; Nemes B; Bobek I; Kristóf V; Selmeci L; Acsády G Magy Seb; 2001 Dec; 54 Suppl():69-73. PubMed ID: 11816152 [TBL] [Abstract][Full Text] [Related]
25. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406 [TBL] [Abstract][Full Text] [Related]
26. [Arterial thrombolysis in the lower extremity in vascular surgical practice]. Entz L; Laczkó A; Bíró G; Széphelyi K; Simonffy A; Járányi Z Magy Seb; 2007 Jan; 60(1):501-5. PubMed ID: 17474303 [TBL] [Abstract][Full Text] [Related]
27. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Collen D; Stassen JM; De Cock F Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288 [TBL] [Abstract][Full Text] [Related]
28. Enhanced streptokinase-induced thrombolysis using heparin in a rabbit model. Kolts RL; Maki HS; Kuehner ME; Roberts RC; Sautter RD J Invest Surg; 1989; 2(4):431-6. PubMed ID: 2488007 [TBL] [Abstract][Full Text] [Related]
29. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934 [TBL] [Abstract][Full Text] [Related]
30. Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis. Leach JK; Patterson E; O'Rear EA Thromb Haemost; 2004 Jun; 91(6):1213-8. PubMed ID: 15175809 [TBL] [Abstract][Full Text] [Related]
32. Use of plasminogen activators in venous thrombosis. Hirsh J; Turpie AG World J Surg; 1990; 14(5):688-93. PubMed ID: 2238671 [TBL] [Abstract][Full Text] [Related]
33. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303 [TBL] [Abstract][Full Text] [Related]
34. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster. Stassen JM; Nyström A; Hoylaerts M; Collen D Circulation; 1995 Mar; 91(5):1330-5. PubMed ID: 7867170 [TBL] [Abstract][Full Text] [Related]
35. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Peuhkurinen K; Risteli L; Jounela A; Risteli J Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022 [TBL] [Abstract][Full Text] [Related]
36. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Agnelli G; Buchanan MR; Fernandez F; Van Ryn J; Hirsh J Blood; 1985 Aug; 66(2):399-401. PubMed ID: 4040410 [TBL] [Abstract][Full Text] [Related]
38. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Martin U; Kohnert U; Stern A; Popp F; Fischer S Thromb Haemost; 1996 Dec; 76(6):1096-101. PubMed ID: 8972037 [TBL] [Abstract][Full Text] [Related]
39. Use of recombinant tissue-plasminogen activator for aortic thrombolysis in a hypoproteinemic dog. Clare AC; Kraje BJ J Am Vet Med Assoc; 1998 Feb; 212(4):539-43. PubMed ID: 9491162 [TBL] [Abstract][Full Text] [Related]
40. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]